Adjuvant use of multispecies probiotic in the treatment of peri‐implant mucositis: A randomized controlled trial

• DOI: 10.1111/jcpe.13663
• Publication Date: 2022-05-30T07:37:51Z
• Authors: Sandro I. Santana; Pedro H. F. Silva; Sérgio L. Salvador; Renato C. V. Casarin; Flávia A. C. Furl...; Michel R. Messora
• Keywords: Lactobacillus rhamnosus; Bleeding on probing; Mucositis; Lactobacillus paracasei; Lactobacillus salivarius

Abstract Aim This randomized placebo‐controlled clinical trial evaluated the effects of multispecies probiotic containing Lactobacillus rhamnosus HN001™, paracasei Lpc‐37®, and Bifidobacterium animalis subsp lactis HN019™ as an adjunct to mechanical debridement (MD) on changes in bleeding probing (BOP) edentulous patients with peri‐implant mucositis (PiM). Materials Methods Patients were randomly assigned test (probiotic) or control (placebo) groups. All sites PiM received MD topical gel application (probiotic placebo) at baseline 12 weeks. After initial MD, consumed placebo capsules twice a day for Clinical (modified sulcus index [mSBI]; modified plaque [mPI]; depth [PD]; BOP) immunological parameters collected after 24 Data statistically analysed ( p < .05). Results Thirty‐six recruited. The group presented higher prevalence .05) cases restored health weeks than did (72.2% 33.3%, respectively). No significant difference was observed between n = 18) groups mPI PD. mSBI %—score 0 When compared baseline, both reduced BOP lower (mean −14.54%; 95% confidence interval [CI] −28.87 0.22; .0163) −12.56%; CI −26.51 1.37; .0090) At weeks, only levels interleukin (IL)‐1β, IL‐6, IL‐8, tumour necrosis factor (TNF)‐α those Conclusions (administered locally systemically) L. B. repeated promotes additional benefits treatment (ClinicalTrials.gov NCT04187222).